Sales up 14% to €11.67 million Significant increase in operating expenses to €12.58 million (+20%) due to the growing internationalization of connected products activities Positive
Record revenues up 20% to €10.2 million Cost control with a 3.3% increase in operating expenses Positive annual net income of €0.3 million Mallya's first commercial launches
Business continues to grow at a sustained pace in the first half of 2021 Two highly impactful announcements for iBiopsy and iCRO business units during Q3, 2021 Third quarter revenue
Plant Advanced Technologies PAT: 2020 Annual Results
Search jobs
A limited impact on net income from the health crisis: - € 0.7m
A sound financial position: net debt of € 4.32m for total equity of € 9.33m.
2021 outlook
Deployment of a marketing strategy focused on adopting a product catalog and indirect distribution.
Continuing internal research to prepare for the launch of new disruptive products.
All subsidiaries have excellent visibility for their businesses.
VANDŒUVRE-LÈS-NANCY, France (BUSINESS WIRE) Regulatory News:
PAT SA INCOME STATEMENT HIGHLIGHTS AT DECEMBER 31, 2020
(Parent company financial statements - The annual financial statements presented below are not consolidated and concern exclusively the parent company PAT SA. In consequence, they do not include the subsidiaries StratiCELL, Cellengo (wholly-owned), PAT Zerbaz (99%-held), Temisis (98%-held) and Couleurs de Plantes (66%-held).